Araris, one of PSIs youngest spin-offs, today announced that they have successfully closed a CHF 15.2M seed round with a group of previous and new investors. The funds raised will allow the further development of the ADC linker technology licensed out by PSI and hopefully identify potent drug candidates.
Dr. Philipp Spycher, CEO of Araris Biotech AG began his entrepreneurial endeavors with the PSI Founder Fellowship that helped kick-start his ideas of building a business around the technology that he helped to develop at PSI.
PSI applauds this development and looks forward to a bright future for Araris.
ADCs (Anbibody Drug Conjugates) consist of highly potent cytotoxic agents conjugated to antibodies through a specific linker. This molecular format enables the highly selective delivery of any payload to the diseased tissue, while healthy parts of the human body are spared.